Immunomodulation for primary prevention of urinary tract infections in patients with spinal cord injury during primary rehabilitation: protocol for a randomized placebo-controlled pilot trial (UROVAXOM-pilot)

Jörg Krebs, Jivko Stoyanov, Jens Wöllner, Ezra Valido, Jürgen Pannek, Jörg Krebs, Jivko Stoyanov, Jens Wöllner, Ezra Valido, Jürgen Pannek

Abstract

Background: Urinary tract infections (UTIs) are common in individuals with neurogenic lower urinary tract dysfunction (NLUTD) following spinal cord injury (SCI). They are not only a great burden for affected individuals, but also cause considerable health costs. Furthermore, recurrent antibiotic treatments of UTIs contribute to the growing problem of bacterial resistance to antimicrobial compounds. Even though there is a multitude of different measures to prevent UTIs in individuals with NLUTD, no clear evidence exists for any of these. Oral immunomodulation with UTI-relevant Escherichia coli lysate may be a promising preventative measure with a good safety profile in individuals with NLUTD. However, currently available data are sparse.

Methods: This is a randomized, quasi-blinded, placebo-controlled, mono-centric pilot trial investigating the feasibility of a main trial regarding the effects of a lyophilized lysate of E. coli strains for oral application (Uro-Vaxom®, OM Pharma SA, Meyrin, Switzerland). There will be two parallel groups of 12 participants each. Individuals with acute SCI (duration SCI ≤ 56 days) from 18 to 70 years of age admitted for primary rehabilitation will be eligible. Blood and urine samples will be taken prior to intervention start, at the end of the intervention, and 3 months after intervention termination. The trial intervention will last 90 days. The participants will not be informed regarding the treatment allocation (quasi-blinded). The nursing staff will prepare the daily dose of the allocated treatment from the original packaging. The trial personnel and the biostatistician will be blinded. Feasibility (e.g., recruitment rate, patient attrition), clinical (e.g., number of symptomatic UTIs), and laboratory parameters (e.g., urinary culture, urinary proteo- and microbiome, blood cell counts) as well as adverse events will be collected.

Discussion: Effective and efficient measures for the prevention of UTIs in individuals with NLUTD are urgently needed. If the conclusion of this pilot is positive regarding feasibility, the effects of oral immunomodulation with a E. coli lysate will be investigated in a larger, sufficiently powered, multi-center trial.

Trial registration: ClinicalTrials.gov NCT04049994 . Registered on 8 August 2019.

Keywords: Escherichia coli; Feasibility trial; Immunomodulation; Immunostimulation; Immunotherapy; Neurogenic lower urinary tract dysfunction; Spinal cord injury; SwiSCI; SwiSCI biobank; Urinary tract infection; Uro-Vaxom®.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments. UTIs urinary tract infections

References

    1. Welk B, Liu K, Winick-Ng J, Shariff SZ. Urinary tract infections, urologic surgery, and renal dysfunction in a contemporary cohort of traumatic spinal cord injured patients. Neurourol Urodyn. 2017;36(3):640–647. doi: 10.1002/nau.22981.
    1. Garcia-Arguello LY, O'Horo JC, Farrell A, Blakney R, Sohail MR, Evans CT, et al. Infections in the spinal cord-injured population: a systematic review. Spinal Cord. 2017;55(6):526–534. doi: 10.1038/sc.2016.173.
    1. Vasudeva P, Madersbacher H. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored. Neurourol Urodyn. 2014;33(1):95–100. doi: 10.1002/nau.22378.
    1. Pavlicek D, Krebs J, Capossela S, Bertolo A, Engelhardt B, Pannek J, et al. Immunosenescence in persons with spinal cord injury in relation to urinary tract infections -a cross-sectional study. Immun Ageing. 2017;14(1):22. 10.1186/s12979-017-0103-6.
    1. Krebs J, Wollner J, Pannek J. Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(9):682–686. doi: 10.1038/sc.2015.214.
    1. Jahromi MS, Mure A, Gomez CS. UTIs in patients with neurogenic bladder. Current Urology Reports. 2014;15(9):433. doi: 10.1007/s11934-014-0433-2.
    1. White BAB, Dea N, Street JT, Cheng CL, Rivers CS, Attabib N, Kwon BK, Fisher CG, Dvorak MF. The economic burden of urinary tract infection and pressure ulceration in acute traumatic spinal cord injury admissions: evidence for comparative economics and decision analytics from a matched case-control study. J Neurotrauma. 2017;34(20):2892–2900. doi: 10.1089/neu.2016.4934.
    1. Renard J, Ballarini S, Mascarenhas T, Zahran M, Quimper E, Choucair J, Iselin CE. Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther. 2014;4(1):125–135. doi: 10.1007/s40121-014-0054-6.
    1. Martins CF, Bronzatto E, Neto JM, Magalhaes GS, D'Anconna CA, Cliquet A., Jr Urinary tract infection analysis in a spinal cord injured population undergoing rehabilitation--how to treat? Spinal Cord. 2013;51(3):193–195. doi: 10.1038/sc.2012.104.
    1. Blok B, Castro-Diaz D, Del Popolo G, Groen J, Hamid R, Karsenty G, et al. Guidelines on neuro-urology; 2020
    1. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111–119. doi: 10.1016/j.ijantimicag.2008.08.011.
    1. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47(4):542–548. doi: 10.1016/j.eururo.2004.12.009.
    1. Hachen HJ. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol. 1990;143(4):759–762. doi: 10.1016/S0022-5347(17)40084-X.
    1. Krebs J, Fleischli S, Stoyanov J, Jürgen P. Effects of oral immunomodulation therapy on urinary tract infections in individuals with chronic spinal cord injury – a retrospective cohort study. Neurourol Urodynam. 2018;38(1):346–352. doi: 10.1002/nau.23859.
    1. Wade DT, Cooper J, Peckham N, Belci M. Immunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial. Clin Rehabil. 2020;34(12):1458–1464. doi: 10.1177/0269215520946065.
    1. Kim Y, Cho MH, Do K, Kang HJ, Mok JJ, Kim MK, et al. Incidence and risk factors of urinary tract infections in hospitalised patients with spinal cord injury. J Clin Nurs. 2021. 10.1111/jocn.15763.
    1. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut Statist. 2005;4:287–91. doi: 10.1002/pst.185.
    1. Price TK, Dune T, Hilt EE, et al. The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms. J Clin Microbiol. 2016;54:1216–22. doi: 10.1128/JCM.00044-16.
    1. Krebs J, Wollner J, Pannek J. Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54:682–6. doi: 10.1038/sc.2015.214.
    1. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–164. doi: 10.1016/j.conctc.2018.08.001.
    1. Levett KM, Roberts CL, Simpson JM, Morris JM. Site-specific predictors of successful recruitment to a perinatal clinical trial. Clin Trials. 2014;11(5):584–589. doi: 10.1177/1740774514543539.
    1. Thoma A, Farrokhyar F, McKnight L, Bhandari M. Practical tips for surgical research: how to optimize patient recruitment. Can J Surg. 2010;53:205–210.
    1. Bevan EG, Chee LC, McGhee SM, McInnes GT. Patients’ attitudes to participation in clinical trials. Br J Clin Pharmacol. 1993;35(2):204–207. doi: 10.1111/j.1365-2125.1993.tb05687.x.
    1. Krebs J, Katrin Brust A, Tesini S, Guler M, Mueller G, Velstra IM, Frotzler A. Study participation rate of patients with acute spinal cord injury early during rehabilitation. Spinal Cord. 2015;53(10):738–742. doi: 10.1038/sc.2015.73.
    1. Riegger T, Conrad S, Schluesener HJ, Kaps HP, Badke A, Baron C, Gerstein J, Dietz K, Abdizahdeh M, Schwab JM. Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience. 2009;158(3):1194–1199. doi: 10.1016/j.neuroscience.2008.08.021.
    1. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189–199.
    1. Massa LM, Hoffman JM, Cardenas DD. Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. J Spinal Cord Med. 2009;32(5):568–573. doi: 10.1080/10790268.2009.11754562.
    1. Bottex C, Martin A, Fontanges R. Action of a mycotoxin (diacetoxyscirpenol) on the immune response of the mouse--interaction with an immunomodulator (OM-89) Immunopharmacol Immunotoxicol. 1990;12(2):311–325. doi: 10.3109/08923979009019675.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa